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The use of dried blood spots (DBS) has greatly facili­
tated genetic and metabolic screening of newborns by 
simplifying sample collection, storage and transport. 
Measuring the HIV­1 burden from whole blood dried 
on filter paper provides a suitable alternative for low­
technology settings with limited access to laboratory facilities, such as sub­
Saharan Africa (SSA). Nucleic acids in DBS have been shown to be stable 
for several months at room temperature, provided the DBS specimens are 
thoroughly dried and are stored with desiccant.[1­4] DBS specimens can 
therefore be collected at remote rural sites and transported to a central or 
regional testing laboratory without refrigeration. DBS are user­friendly 
and cost­effective in resource­limited settings, their ability being demon­
strated to correctly identify virological failure.[5­7] DBS use may therefore 
represent a paradigm shift in accessibility to virological testing for HIV 
infection. Indeed, the Diagnostic Access Initiative (http://www.unaids.org) 
signed in Melbourne during the 20th International AIDS Conference in 
July 2014, specifically focused on ensuring that all people accessing HIV 
treatment should have ready access to tests that monitor levels of the virus 
in their bodies, and underlined the importance of developing new and 
affordable viral load and early infant diagnosis technology.
The objective of this study was to evaluate and validate, in SSA, HIV 
viral load measurement from DBS with a reliable, all­automated, standard 
commercial assay, the Abbott m2000 (Abbott Molecular, USA). The 
study was performed in two healthcare settings in two different countries, 
Malawi and Mozambique, within the health centre network of the 
DREAM (Drug Resource Enhancement against AIDS and Malnutrition) 
Programme of the Community of Sant’Egidio. Briefly, DREAM is a holistic 
programme started in December 2001 for the care of people living with 
HIV and the prevention of mother­to­child transmission (http://dream.
santegidio.org). To date, the DREAM programme is active in ten countries 
(Mozambique, Malawi, Tanzania, Kenya, Republic of Guinea, Guinea 
Bissau, Cameroon, Democratic Republic of Congo, Angola and Nigeria) 
in SSA, with a network of 42 health centres and 20 laboratories. Because 
of the hub infrastructure used for health centres and laboratories in every 
country, only those facilities with molecular biology laboratories perform 
the HIV viral load testing. The possibility of using DBS to deliver samples 
for HIV viral load may therefore increase the accessibility to the test in 
rural areas and small settings. In this study, results were analysed according 
to different thresholds of HIV­RNA in order to develop an HIV viral load 
testing procedure from DBS that could be implemented in SSA.
Methods
Paired plasma and DBS samples were collected from 119 patients in 20 
centres referring to the DREAM Health Centre of Blantyre, Malawi, and 
from 158 patients in 23 centres referring to the Centro Para Criança, 
Maputo, Mozambique. The DREAM Programme has been approved 
by the National AIDS Commission of Malawi and by the Ministério de 
Saude – Direcção de Planificação e Cooperação of Mozambique.
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Background. The use of dried blood spots (DBS) for HIV­1 viral load quantification can greatly improve access to viral monitoring for 
HIV­infected patients receiving treatment in resource­limited settings.
Objectives. To evaluate and validate HIV viral load measurement from DBS in sub­Saharan Africa, with a reliable, all­automated, standard 
commercial assay such as the Abbott m2000.
Methods. A total of 277 DBS were collected in different health centres in Malawi and Mozambique and analysed for viral load determination 
using the Abbott m2000 assay with the corresponding plasma samples as gold standard. Samples were extracted using the m2000SP 
automatic extractor and then processed as the plasma samples using the specific 1.0 mL HIV­RNA DBS protocol.
Results. Among samples with detectable HIV­RNA the correlation between viral load obtained from the paired 131 plasma and DBS 
samples was high (r=0.946). Overall, viral load values between DBS and plasma differed by less than 0.5 log unit in 90.1% of cases and by less 
than 1 log unit in 100% of cases. Using a threshold of 1 000 copies/mL (defining virological failure in resource­limited settings), sensitivity 
was 94.2% and specificity 98.6%, and both positive and negative predictive values were high (98.5% and 94.5%, respectively).
Conclusion. DBS extracted and processed using the Abbott automated system can be reliably used in resource­limited setting to diagnose 
virological failure.
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Eight hundred microlitres of plasma were used to extract nucleic 
acids with the Abbott automatic extractor, Sample Preparation System 
(m2000SP). The nucleic acids extracted by m2000SP were used for 
real­time amplification with the Abbott m2000RT using the 0.6 mL 
HIV­RNA protocol. DBS (50 µL of peripheral blood per spot) were 
air­dried overnight and stored in a plastic bag with desiccant at room 
temperature. DBS eluate was obtained by incubating two of five spots 
for each sample with 1.7 mL of Abbot Bulk lysis buffer for 15 minutes at 
room temperature with constant mixing. The eluate was transferred to a 
test tube and extracted using the m2000SP automatic extractor with the 
1.0 mL HIV­1 RNA DBS Exp V04 protocol. The extracted material was 
then quantitated as the plasma samples with the real­time PCR Abbott 
m2000RT using the corresponding 1 mL DBS protocol, according to the 
manufacturer’s instructions.
All HIV­RNA values were log10 transformed before analysis. Results 
reported as not detected and below detection limit (<40 copies/mL) were 
analysed considering a value of 1.6 log10 HIV­RNA per mL. Results were 
expressed as means and standard deviations (SDs). Viral load measured in 
DBS and paired plasma samples were compared by the Pearson correlation 
analysis. The Bland­Altman method[8] was used for analysis of concordance 
between the results obtained from plasma and those obtained from DBS. 
Statistical analysis was done using SPSS version 22 (IBM, USA).
Results
A total of 277 paired plasma and DBS samples were analysed. Samples 
were divided according to the HIV­RNA level in plasma: ≤2 log10 
(n=109), 2 log10 (range 2.11 ­ 2.99; n=30), 3 log10 (range 3.10 ­ 3.99; 
n=81), 4 log10 (range 4.04 ­ 4.96; n=29) and ≥5 log10 (range 5.03 ­ 
6.84; n=28). Samples were analysed after a mean time of 1 week after 
collection and storage (at room temperature).
Agreement between detectable and undetectable viral load for 
plasma and DBS was seen in 83.0% of cases. In 16.6% of cases (n=46), 
HIV­RNA was not detectable in DBS while measurable levels were 
present in plasma (between 1.76 and 3.83 logs; mean 2.48). One 
DBS gave a result of 3.54 log10 while the corresponding plasma level 
was <1.6 log10. In all other cases of undetectable viral load in plasma 
(n=99), HIV­RNA was not detectable in DBS. The lowest HIV­RNA 
level detected by DBS was 616 copies/mL.
Using the 40 copies/mL threshold, the test had relatively good sensitivity 
(74%), high specificity (99%) and a high positive predictive value (99.2%) 
(Table 1). Negative predictive value was low (68.3%) as an effect of the low 
rate of detection when plasma HIV­RNA was below 3 log copies/mL.
Among samples with detectable HIV­RNA, the correlation between 
viral load values obtained from the paired 131 plasma and DBS 
samples was high (Pearson correlation coefficient 0.946 and R2=0.895) 
(Fig. 1). The mean (SD) difference between the measured viral load 
in DBS and in plasma was 0.15 (0.27) log copies/mL. HIV­RNA 
levels obtained from DBS were higher than in plasma in 70.2% of the 
samples. However, this over­quantification was observed mainly in 
specimens with a plasma viral load of <3 000 copies/mL (mean (SD) 
difference 0.38 (0.19)), while the difference for samples with a plasma 
viral load of >3 000 copies/mL was negligible (0.09 (0.26)). Overall, 
viral load values between DBS and plasma differed by <0.5 log unit 
in 90.1% of cases and by <1 log unit in 100%.
Agreement between the two methods was calculated by the Bland­
Altman method,[8] in which the differences between individual viral 
load results from plasma and DBS are plotted against the mean of the 
two results. In Fig. 2 it can be seen that the data are well scattered over 
the mean along the overall range of viral load examined and that all 
Table 1. Sensitivity, specificity, positive and negative predictive values (95% confidence intervals) of DBS according to the limit of 
detection of the assay (A) and the threshold of 1 000 copies/mL (B)
Plasma
A ≥40 copies/mL <40 copies/mL Total
DBS ≥40 copies/mL 131 1 132 Sensitivity 74% (66.9 ­ 80.3)
<40 copies/mL 46 99 145 Specificity 99% (94.5 ­ 99.8)
Total 177 100 277 PPV 99.2% (95.8 ­ 99.9)
NPV 68.3% (60.0 ­ 75.8)
Plasma
B ≥1 000 copies/mL <1 000 copies/mL Total
DBS ≥1 000 copies/mL 130 2 132 Sensitivity 94.2% (88.9 ­ 97.5)
<1 000 copies/mL 8 137 145 Specificity 98.6 % (94.9 ­ 99.8)
Total 138 139 277 PPV 98.5% (94.6 ­ 99.8)
NPV 94.5% (89.4 ­ 97.6)
PPV = positive predictive value; NPV = negative predictive value.
Fig. 1. Comparison of viral load in DBS and corresponding values in plasma 
only for samples with detectable viral load.
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but five samples were within the 1.96 SD limits, underlining the good 
agreement between the two methods.
The detection rate with DBS was 90.1% when plasma levels 
were  >1 000  copies/mL. Categorising the samples according to this 
1 000  copies/ mL threshold, of the 138 samples with a viral load 
of >1 000 copies/mL, 8 (5.8%) had a DBS viral load of <1 000 copies/ ml 
and therefore would have been missed if the virological failure 
threshold had been set at 1 000 copies/mL. Of the 139 samples with 
a plasma viral load of <1 000 copies/mL, only 2 (1.4%) had an HIV­
RNA in DBS of >1 000 copies/ml and could represent false virological 
failure detection. With the threshold of 1 000 copies/mL, sensitivity was 
94.2%, specificity 98.6% and positive and negative predictive values 
98.5% and 94.5%, respectively (Table 1). The agreement between DBS 
and plasma HIV­RNA quanti fication at the 1 000 copies/mL threshold 
was high, as demon strated by the Kappa coefficient value of 0.928 
(standard error 0.022, p<0.001).
Discussion
Several reports have been published on the use of DBS for viral load 
quantification using different methodologies, including the Abbott 
assay.[9] In the great majority of cases the results were comparable with 
those obtained from plasma. However, the use of DBS collected and 
prepared in real­world conditions for viral load monitoring with the 
automated Abbott assay has been reported in only a few studies.[10­12] 
Our data, obtained from DBS collected and processed by local personnel 
in Malawi and Mozambique, showed that DBS gave comparable results 
in respect of the reference method in the range from 3 to 7 logs copies/
mL. However, the detection rate below the threshold of 1 000 copies/mL 
was lower, as reported in other articles,[2,13] although the lowest plasma 
RNA value at which DBS RNA was detectable was 616 copies/mL in line 
with the threshold of 550 copies/mL previously reported for this assay. [5] 
The modest over­quantification that we observed with DBS can be 
ascribed to the presence of HIV­DNA and intracellular RNA and seems 
to have a greater impact on samples with a low viral load (in our study 
<3 000 copies/mL), as previously reported.[4,11,14]
The 2013 HIV treatment guidelines of the World Health Organi­
zation[15] indicate a threshold of 1 000 copies/mL of HIV­RNA to 
define virological failure using plasma, and suggest use of a higher, 
although undefined, threshold when using DBS. In previous studies 
performed with the Abbott system, sensitivity for the detection of 
virological failure at 1  000  copies/mL was between 75% and 100% 
and specificity was between 82% and 97%.[10,11] In our study, very high 
positive and negative predictive values were observed when using a 
threshold of 1 000 copies/mL, suggesting that even with the use of DBS 
the threshold of 1 000 copies/mL can provide reliable results, given the 
specificity of 98.6% at this threshold.
The last systematic review of the use of DBS for monitoring HIV 
viral load[9] emphasised the need for a standardised approach for 
sampling, storing and processing DBS samples in order to establish 
whether DBS could reliably replace plasma specimens to identify 
virological failure. Our study suggests that DBS on filter paper, stored 
at room temperature and processed with an automated extractor, 
followed by real­time quantification of HIV­RNA, could represent a 
standard to be applied in resource­limited settings.
Conclusion
Our study demonstrated that HIV­1 quantification from DBS using 
a standardised commercial assay provides reliable identification of 
virological failure in SSA.
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Fig. 2. Bland-Altman analysis of agreement between plasma and DBS. The 
horizontal lines represent the mean difference and 1.96 SDs.
